Nicolette Sherman
Human Resources Officer bei CERTARA, INC.
Vermögen: 435 521 $ am 31.03.2024
Profil
Nicolette D.
Sherman is currently the Chairman at Deirdres House and the Chief Human Resources Officer at Certara, Inc. She previously worked as the VP-North America Human Resources Operations at Sanofi Corp.
from 2008 to 2020 and as the Chief Human Resources Officer at Oyster Point Pharma, Inc. from 2020 to 2021.
Sherman has a graduate degree from Rutgers State University of New Jersey and a graduate degree from the University of Delaware.
She also has an undergraduate degree from Lehigh University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CERTARA, INC.
0,02% | 01.04.2024 | 24 358 ( 0,02% ) | 435 521 $ | 31.03.2024 |
Aktive Positionen von Nicolette Sherman
| Unternehmen | Position | Beginn |
|---|---|---|
| CERTARA, INC. | Human Resources Officer | 13.07.2021 |
| Deirdres House | Chairman | - |
Ehemalige bekannte Positionen von Nicolette Sherman
| Unternehmen | Position | Ende |
|---|---|---|
| OYSR POIN | Human Resources Officer | 01.07.2021 |
| Sanofi Corp. | Corporate Officer/Principal | 01.04.2020 |
Ausbildung von Nicolette Sherman
| Rutgers State University of New Jersey | Graduate Degree |
| Lehigh University | Undergraduate Degree |
| University of Delaware | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CERTARA, INC. | Technology Services |
| Private Unternehmen | 3 |
|---|---|
| Sanofi Corp. | |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
| Deirdres House |
